PATENT CLAIM ANALYSIS

Application Number: 15938729
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "423000"]

Abstract:
The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.

Claim (Index 9):
The compound according to any one of the preceding claims, wherein said compound is administered concomitantly or separately with at least one compound selected from the group comprising calcium channel blockers, magnesium sulfate, selective prostaglandin modulators, beta-2-adrenergic agonists, beta-3-adrenergic receptor agonists, and/or corticosteroids.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 90.0
- Lexical Diversity: 1.21277
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14479664', '15476325', '14571615', '14735215', '10480992']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7839380264449329
- 35 USC 102 Novelty (BERT): 0.562068549093379
- Combined Prediction Score: 0.7617510787097775
- Mean Citation Score: 366.683408
- Max Citation Score: 432.80896
- Similarity Product: 399.8374783605957

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test